Tymlos has a greater attachment to parathyroid receptors called RG conformation. This attachment leads to rapid and swift increase in intermittant signaling. Forteo binds weakly to RG but more firmly to RO receptor which results in prolonged signaling of cells and prolonged calcemic responses. Intermittant signaling results in greated bone growth. Prolonged signaling supports resorptive action.
One other piece of on line information:
bioavailability of 80mcg Tymlos 36mc
bioavailability of 20mcg Forteo 19mcg
Some really smart person could volunteer to straighten all this out.

I wonder if reduced dose of Tymlos provides a greater percentage of bioavailable abloparatide.
With the RG advantage Tymlos must have a wider anabolic window than Forteo by far.